
TMA Precision Health: Enhancing lives with genome sequencing for rare disease treatment.
TMA Precision Health, founded with a mission to improve the lives of rare disease patients, focuses on ending the diagnostic odyssey for these individuals. The company offers genome sequencing services and a research platform that provides comprehensive information about diagnosed diseases, including related genes, repurposed drugs, existing care options, and active clinical trials. Their vision is to ensure that rare disease patients worldwide receive the medical care they need to lead happy and healthy lives.
Notable affiliated individuals and investors include experts in genomics and healthcare innovation, although specific names are not provided. Key achievements of TMA Precision Health include the development of their advanced research platform, which significantly accelerates the diagnostic process and treatment options for rare diseases. The overall impact of TMA Precision Health lies in its potential to transform the healthcare landscape for rare disease patients by providing timely and accurate diagnostic information, thereby improving patient outcomes and quality of life.

Toma Biosciences
tomabio.com

Variantyx
variantyx.com

Precision Theranostics

Genome Insight

Probably Genetic

Genome Medical
genomemedical.com

Rare Disease Data Trust
finding-rare.com

ThinkGenetic
thinkgenetic.com

Sequegenics
sequegenics.com

Genetron Health
genetronhealth.com

Geneial
geneial.com

Unite Genomics

Ariel Precision Medicine
arielmedicine.com

Inform Genomics
informgenomics.com

Base5 Genomics
b5genomics.com
Companies similar to TMA Precision Health include Toma Biosciences, Variantyx, Precision Theranostics and Genome Insight.
TMA Precision Health was founded in 2019.
TMA Precision Health's headquarters is located in Boston, MA, US.
TMA Precision Health's most recent funding round was for $20k (USD) in August 2022.
As of Aug 5, 2022, TMA Precision Health has raised a total of $20k (USD).
TMA Precision Health has 3 employees as of Feb 4, 2024.